» Articles » PMID: 23878286

Recurrent Glioblastoma: Optimum Area Under the Curve Method Derived from Dynamic Contrast-enhanced T1-weighted Perfusion MR Imaging

Overview
Journal Radiology
Specialty Radiology
Date 2013 Jul 24
PMID 23878286
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether the ratio of the initial area under the time-signal intensity curve (AUC) (IAUC) to the final AUC--or AUCR--derived from dynamic contrast material-enhanced magnetic resonance (MR) imaging can be an imaging biomarker for distinguishing recurrent glioblastoma multiforme (GBM) from radiation necrosis and to compare the diagnostic accuracy of the AUCR with commonly used model-free dynamic contrast-enhanced MR imaging parameters.

Materials And Methods: The institutional review board approved this retrospective study and waived the informed consent requirement. Fifty-seven consecutive patients with pathologically confirmed recurrent GBM (n = 32) or radiation necrosis (n = 25) underwent dynamic contrast-enhanced MR imaging. Histogram parameters of the IAUC at 30, 60, and 120 seconds and the AUCR, which included the mean value at the higher curve of the bimodal histogram (mAUCR(H)), as well as 90th percentile cumulative histogram cutoffs, were calculated and were correlated with final pathologic findings. The best predictor for differentiating recurrent GBM from radiation necrosis was determined by means of receiver operating characteristic (ROC) curve analysis.

Results: The demographic data were not significantly different between the two patient groups. There were statistically significant differences in all of the IAUC and AUCR parameters between the recurrent GBM and the radiation necrosis patient groups (P < .05 for each). ROC curve analyses showed mAUCR(H) to be the best single predictor of recurrent GBM (mAUCR(H) for recurrent GBM = 0.35 ± 0.11 [standard deviation], vs 0.19 ± 0.17 for radiation necrosis; P < .0001; optimum cutoff, 0.23), with a sensitivity of 93.8% and a specificity of 88.0%.

Conclusion: A bimodal histogram analysis of AUCR derived from dynamic contrast-enhanced MR imaging can be a potential noninvasive imaging biomarker for differentiating recurrent GBM from radiation necrosis.

Supplemental Material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13130016/-/DC1.

Citing Articles

Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning-Based Prediction Models to Distinguish Glioblastomas from Single Brain Metastases.

Hosseini S, Servaes S, Hall B, Bhaduri S, Rajan A, Rosa-Neto P Diagnostics (Basel). 2025; 15(1.

PMID: 39795566 PMC: 11720653. DOI: 10.3390/diagnostics15010038.


Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O-methylguanine-methyltransferase promoter methylation status.

Yadav V, Mohan S, Agarwal S, de Godoy L, Rajan A, Nasrallah M Neurooncol Adv. 2024; 6(1):vdae159.

PMID: 39502470 PMC: 11535496. DOI: 10.1093/noajnl/vdae159.


The value of predicting neoadjuvant chemotherapy early efficacy in nasopharyngeal carcinoma based on amide proton transfer imaging and diffusion weighted imaging.

Zhang Y, Li G, Chen J, Jiang M, Gao Y, Li K Quant Imaging Med Surg. 2024; 14(10):7330-7340.

PMID: 39429559 PMC: 11485347. DOI: 10.21037/qims-24-188.


Longitudinal Evaluation of DCE-MRI as an Early Indicator of Progression after Standard Therapy in Glioblastoma.

Arevalo-Perez J, Trang A, Yllera-Contreras E, Yildirim O, Saha A, Young R Cancers (Basel). 2024; 16(10).

PMID: 38791921 PMC: 11119591. DOI: 10.3390/cancers16101839.


Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient.

Kamimura K, Nakano T, Hasegawa T, Nakajo M, Yamada C, Kamimura Y Cancer Imaging. 2023; 23(1):114.

PMID: 38037172 PMC: 10691025. DOI: 10.1186/s40644-023-00639-7.